Acedoben.
Research-backed compound with potential health benefits. It's been investigated for a potential role in modulating the immune system, particularly in response to certain viruses. It's a derivative of PABA.
Reviewed March 2026
- Category
- Compound
What Acedoben is, and what it does.
- Does it work
- It suits someone who has met it inside the inosine complex and wants to know what the acid part contributes. Standalone human research on it is old and sparse.
- How much to take
- Dosing isn't well established. Older research protocols used 500-1000mg multiple times per day. There is no modern consensus.
- Time to feel it
- Nothing to notice day to day. Older protocols ran across weeks, and nobody has measured a time to a felt effect in modern work.
- The first dose
- Nothing. Any potential effects would be cumulative and very subtle over weeks, not hours.
- With regular use
- The theoretical goal is a more resilient immune response. The data isn't strong enough to make that promise. Most people will likely notice no difference at all.
- How well tolerated
- Seems well tolerated for most healthy people, but modern safety data is scarce. The major warning is the interaction with sulfa drugs. Don't mix them.
- How it feels
- No direct sensation has been described for it. Nothing measured points to an energy, mood or calm effect, so whatever it does sits below the level you'd notice.
- The overlooked benefit
- It's the same acetylated form your own enzymes make from PABA, and how fast you make it differs between people: the fast and slow acetylator split has been known for decades.
100 to 250mg a day is where Acedoben works.
Source: Limited pharmacological references
The proof, claim by claim.
These words describe the research, not the molecule's worth. Research strength is how much work stands behind one claim, and it is never a product score.
Acedoben is documented in the library; the clinical read is in the queue. Nothing about the strength of the research prints until the read is done.
- Immune response signalling as part of a fixed-ratio inosine complexRandomised trial
- Solubilising and stabilising role for inosine in that complexNarrative review
- Principal acetylated metabolite of para-aminobenzoic acid in humansNarrative review
- Handling differences between fast and slow acetylatorsCohort study
Questions people ask about Acedoben.
- Is this the same as PABA?
- It's a derivative. Think of it as a close cousin. PABA is more commonly associated with skin and hair claims, while acedoben was studied for immune effects.
- Why is it so hard to find?
- Because it mostly fell out of favor. Newer compounds with much better research have taken its place. It's more of a historical footnote in the supplement world.
- Can I take it with my multivitamin?
- Yes, that should be fine. The main thing to avoid is sulfa-based antibiotics.
- Are there any side effects?
- Side effects are rare at suggested doses. Very high intake might cause some GI upset, but the compound is not well-studied in modern trials.
- Is this a vitamin?
- No. It is related to the B-vitamin family through PABA, but it is not an essential vitamin your body needs to function.
Why these belong in the same formula. Each row says what the basis is, from settled biochemistry through to a trial that measured the pair.
Acedoben is N-acetyl-4-aminobenzoic acid, the acetylated form of PABA, and it hydrolyses back to PABA and acetate. The two are the same molecule either side of an acetyl group.
Potassium aminobenzoate is a salt of the same 4-aminobenzoic acid backbone that acedoben carries in acetylated form. Both deliver the aminobenzoate moiety and their contributions overlap rather than add.
Acedoben is one of three components of inosine acedoben dimepranol, a defined molecular complex in which inosine is combined with acedoben and dimepranol in a fixed stoichiometric ratio. Acedoben in that setting is a counter-ion and solubilising partner rather than a standalone active. Anyone encountering acedoben on a label is most likely seeing it as part of that complex. The relationship is compositional and needs no trial to state.
Acedoben is 4-acetamidobenzoic acid, the N-acetylated form of para-aminobenzoic acid, and N-acetylation in the body is carried out by N-acetyltransferases using acetyl-CoA as the acetyl donor. Coenzyme A is built from pantothenate, which puts pantothenic acid upstream of every acetylation reaction. The link is cofactor supply, not an effect of one on the other. Textbook biochemistry with no citation required.
Para-aminobenzoic acid, the parent of acedoben, is the ring component that bacteria incorporate into dihydropteroate when they build folate from scratch. Humans lack that pathway entirely and must take folate preformed from food or supplements. So the historical grouping of PABA with the B vitamins reflects microbial chemistry, not a human requirement. That distinction is the single most useful thing to say about this molecule.
Aromatic amines are cleared through N-acetylation and competing conjugation routes, and methionine feeds the S-adenosylmethionine pool that drives methylation as a parallel clearance path. Compounds handled by these overlapping routes share a finite conjugation capacity. This describes clearance chemistry rather than a benefit. Included so the metabolic neighbourhood of the molecule is visible.
Benzoic acid derivatives are classically conjugated with glycine to form hippurate-type metabolites for urinary excretion, which is one of the oldest described conjugation reactions in human biochemistry. A substituted benzoic acid such as acedoben sits in that structural family. Glycine availability is one determinant of that conjugation capacity. This is established pathway chemistry, not an efficacy claim.
The B5 form of the same nutrient is listed separately because product labels use both names, and the relationship is identical: pantothenate builds coenzyme A, and coenzyme A carries the acetyl group used in N-acetylation. Where a formula lists B5 rather than pantothenic acid the same upstream link applies. No trial underpins this and none is needed. It is a cofactor statement.
Aldehyde oxidase and xanthine oxidase are molybdenum-dependent enzymes involved in the oxidation of nitrogen heterocycles, including the purine ring of the inosine that acedoben accompanies in its complex. Molybdenum status therefore sits behind part of that clearance chemistry. The connection is to the complex's purine component rather than to acedoben itself. Marked promising because it is inferential, not direct.
Nothing specific on file for Acedoben. Match the label to the daily amount above, and tell your doctor what you take.
Not medical advice. Show the label to your pharmacist.What Acedoben actually does.
Acedoben is the international non-proprietary name for 4-acetamidobenzoic acid, also written N-acetyl-4-aminobenzoic acid: a benzene ring carrying a carboxylic acid at one position and an acetylated amine at the para position.
It is the N-acetylated derivative of para-aminobenzoic acid, and it is also the principal metabolite formed when PABA is acetylated in the body by N-acetyltransferase enzymes using acetyl-CoA as the acetyl donor.
Acetylating the aromatic amine removes its basicity and lowers the molecule's reactivity, while the carboxylic acid keeps it ionised and water-soluble at physiological pH. Those two properties together make it a useful acidic counter-ion in a salt or complex.
Para-aminobenzoic acid is the substrate that bacteria condense with a pterin to make dihydropteroate on the way to folate. Humans have no dihydropteroate synthase and cannot make folate from PABA, which is why PABA is not a human vitamin despite an older literature that grouped it with the B complex.
Where Acedoben comes from.
This is a lab-made molecule, not something extracted from a plant or an animal. It starts as PABA, and a single well-known chemical step attaches an acetyl group to the nitrogen. The result is filtered, recrystallised and tested, then either turned into a salt or combined with inosine to make the three-part complex it is normally sold inside.
Chemically synthesised. The molecule is identical to the one a plant or an animal makes, and building it deliberately means a known purity, a fixed dose and no crop contaminants. For several nutrients this is the only route that reaches a usable amount.
PABA is itself made industrially from toluene-derived intermediates, most commonly by nitration and oxidation to 4-nitrobenzoic acid followed by reduction of the nitro group to the amine
The aromatic amine is acetylated with acetic anhydride or acetyl chloride, a standard and high-yielding reaction that places the acetyl group on the nitrogen rather than on the carboxylic acid
The product is precipitated by acidification and recrystallised from water or aqueous alcohol to remove unreacted PABA, acetic acid and any diacetylated by-product
Melting point, HPLC assay and residual solvent testing establish identity and purity, with residual free PABA controlled as a specified impurity
The acid is either neutralised to a salt or combined with inosine and dimepranol in the fixed ratio that defines the three-component complex
Labels that list acedoben rarely state whether it is present as the free acid, as a salt, or as part of the inosine complex, and the three differ in how much acedoben a stated weight actually contains.
The forms it comes in.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.